Last reviewed · How we verify
NCT05639179
Novel Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL
Phase 1, PHASE2 trial testing UCAR-T Cells in B-cell Acute Lymphoblastic Leukemia in 30 participants. Status unknown.
31 December 2024
Quick facts
| Lead sponsor | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 5 December 2022 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- UCAR-T Cells — full drug profile →
Conditions studied
- B-cell Acute Lymphoblastic Leukemia — all drugs for B-cell Acute Lymphoblastic Leukemia →
- B-ALL — all drugs for B-ALL →
Sponsor
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Who can join
Adults 2 to 75, any sex, with B-cell Acute Lymphoblastic Leukemia or B-ALL. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single-arm, single-center, open-labeled clinical study to evaluate the safety and efficacy of UCAR-T Cells injection for patients with relapsed/refractory(r/r) B-cell Acute Lymphoblastic Leukemia(B-ALL).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05639179
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for B-cell Acute Lymphoblastic Leukemia
Currently open trials in the same condition.
- NCT06326008 — Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-deri · Phase 1 · recruiting
- NCT07153796 — A Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemoth · Phase 2 · recruiting
- NCT06863259 — Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL · Phase 1 · recruiting
- NCT06793241 — Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic Leukemia · EARLY_PHASE1 · recruiting
- NCT06208735 — CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies · Phase 1 · recruiting
Other 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China trials
Trials by the same sponsor.
- NCT06675422 — JY231 Injection for the Treatment of Active Systemic Lupus Erythematosus (SLE) · Phase 1, PHASE2 · recruiting
- NCT06514768 — JY231 (JY231) Injection for the Treatment of B-cell Acute Lymphoblastic Leukemia (B-ALL) · EARLY_PHASE1 · recruiting
- NCT06352281 — Efficacy and Safety of CAR-T Cells Therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP) · Phase 1, PHASE2 · recruiting
- NCT06210243 — C752 for Refractory/Relapsed B Cell Non-Hodgkin Lymphoma · Phase 1 · terminated
- NCT06110208 — Study to Evaluate the Safety and Preliminary Efficacy of CLL1 and CD38 Dual CAR-T in r/r AML · EARLY_PHASE1 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05639179 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
- Last refreshed: 8 December 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05639179.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing